News | May 04, 2026
Lilly posts explosive Q1 2026 results
Lifts full-year outlook as obesity drug boom accelerates
Lifts full-year outlook as obesity drug boom accelerates
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
